The Columbia River Oncology Program (CROP), a community clinical oncology program currently in its twelfth year, is a consortium of three large health care systems in the Portland, Oregon/Vancouver, Washington metropolitan area. These are the Legacy Health System, the Providence Health System and the Southwest Washington Medical Center.
The aims of CROP are to (a) continue to provide and increase clinical cancer research in the community; (b) actively encourage participation of ethnic minority and financially underprivileged groups to participate in cancer treatment, prevention, and control studies; (c) encourage increased participation of non-oncology physicians and the general population in cancer prevention and control studies; and (d) educate both non-oncology physicians and the lay public about cancer treatment, prevention and control. The implementation of the funded application serves to prevent cancer, treat cancer patients at the optimum levels, and to further the knowledge of the cancer disease process in a large metropolitan community, thus meeting the goals of Healthy People 2000. CROP currently affiliates with five research bases: SWOG, NSABP, RTOG, POG, and GOG. All are multi-specialty cooperative groups that supply CROP with NCI approved cancer treatment, prevention, and control protocols that will be utilized over the next five years. The established functioning operational status of CROP includes an Executive Board with representative committee structure, a central office, and actively participating hospital systems. Ninety-five participating physicians and 13 clinical trial nurses are established mature clinical researchers of whom most have been with CROP since its inception. The central office staff handles the administrative aspects of CROP, the large cancer prevention studies, and the quality improvement aspects of cancer treatment and research data collection. Maturation and expertise of the central office computerization of CROP functions, and web site development will facilitate more efficient communication and high quality clinical research. Clinical trial nurses and clinical research associates employed by the consortium hospitals recruit patients to cancer treatment and control protocols, follow these patients for the duration of the study, collect and submit data to the research bases, participate in the quality improvement process, and actively participate in the research base meetings. Each institution employs a pharmacist who manages the investigation drugs for CROP and the pharmacy chair is an active member of the SWOG Pharmacy Committee. CROP investigators and clinical trial nurses actively contribute to the five research base committee activities, including co-authoring scientific papers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA045377-14
Application #
6172329
Study Section
Special Emphasis Panel (ZCA1-SRRB-7 (J4))
Project Start
1987-08-28
Project End
2004-05-31
Budget Start
2000-06-01
Budget End
2001-05-31
Support Year
14
Fiscal Year
2000
Total Cost
$450,273
Indirect Cost
Name
Providence Portland Medical Center
Department
Type
DUNS #
City
Portland
State
OR
Country
United States
Zip Code
97213
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Malhotra, Binu; Moon, James; Kucuk, Omar et al. (2014) Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0329. Head Neck 36:1712-7
Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8

Showing the most recent 10 out of 142 publications